18.49
0.58 (3.24%)
| Previous Close | 17.91 |
| Open | 17.92 |
| Volume | 313,730 |
| Avg. Volume (3M) | 341,650 |
| Market Cap | 668,284,032 |
| Price / Sales | 8.98 |
| Price / Book | 3.58 |
| 52 Weeks Range | |
| Earnings Date | 8 May 2025 |
| Profit Margin | -62.50% |
| Operating Margin (TTM) | -69.33% |
| Diluted EPS (TTM) | -1.25 |
| Quarterly Revenue Growth (YOY) | 42.30% |
| Total Debt/Equity (MRQ) | 12.03% |
| Current Ratio (MRQ) | 17.36 |
| Operating Cash Flow (TTM) | -36.90 M |
| Levered Free Cash Flow (TTM) | -26.02 M |
| Return on Assets (TTM) | -17.46% |
| Return on Equity (TTM) | -41.39% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Bearish | Bearish |
| Medical Devices (Global) | Bearish | Bearish | |
| Stock | CeriBell, Inc. | Bearish | - |
AIStockmoo Score
| Analyst Consensus | -0.5 |
| Insider Activity | -2.0 |
| Price Volatility | -2.0 |
| Technical Moving Averages | 3.5 |
| Technical Oscillators | 2.0 |
| Average | 0.20 |
|
CeriBell Inc is a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. The Company has developed the Ceribell System, a novel, point-of-care electroencephalography (EEG) platform specifically designed to address the unmet needs of patients in the acute care setting. By combining proprietary, highly portable and rapidly deployable hardware with sophisticated artificial intelligence (AI) powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| % Held by Insiders | 10.51% |
| % Held by Institutions | 85.28% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Red Tree Management, Llc | 31 Mar 2025 | 2,205,661 |
| Yu Fan | 31 Mar 2025 | 1,222,202 |
| Abg-Wtt Global Life Science Capital Partners Gp Ltd | 31 Mar 2025 | 1,088,101 |
| Board Of Trustees Of The Leland Stanford Junior University | 31 Mar 2025 | 623,751 |
| 52 Weeks Range | ||
| Median | 32.00 (73.07%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Ladenburg Thalmann | 04 Apr 2025 | 32.00 (73.07%) | Buy | 18.44 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| ROBERTSON REBECCA B | - | 17.77 | -18,633 | -331,221 |
| Aggregate Net Quantity | -18,633 | |||
| Aggregate Net Value ($) | -331,221 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 17.77 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| ROBERTSON REBECCA B | Director | 18 Jun 2025 | Automatic sell (-) | 11,188 | 17.80 | 199,146 |
| ROBERTSON REBECCA B | Director | 17 Jun 2025 | Automatic sell (-) | 7,445 | 17.74 | 132,074 |
| Date | Type | Details |
|---|---|---|
| 20 Jun 2025 | Announcement | AI Tools That Talk, Scan, and Save Lives Are Reshaping the Investment Landscape |
| 20 May 2025 | Announcement | Ceribell to Participate in the William Blair 45th Annual Growth Stock Conference |
| 08 May 2025 | Announcement | Ceribell Reports First Quarter 2025 Financial Results |
| 30 Apr 2025 | Announcement | Ceribell Receives FedRAMP® High Authorization, Expanding Approval for Its AI-Powered Point-of-Care EEG Across Federal Healthcare Systems |
| 30 Apr 2025 | Announcement | Ceribell to Participate in the Bank of America Securities 2025 Health Care Conference |
| 24 Apr 2025 | Announcement | Ceribell to Report First Quarter 2025 Financial Results on May 8, 2025 |
| 15 Apr 2025 | Announcement | FDA Clears Ceribell’s Clarity™ Algorithm for Pediatric Patients, Making Ceribell the First and Only FDA-Cleared AI Technology for Detection of Electrographic Seizures in Patients Ages 1 Year and Older |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |